Validation of Chinese version of the 5-item WHO well-being index in type 2 diabetes mellitus patients.
Depression
Reliability
Type 2 diabetes
Validity
WHO-5
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
29 Nov 2023
29 Nov 2023
Historique:
received:
22
06
2023
accepted:
15
11
2023
medline:
1
12
2023
pubmed:
30
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
For better disease management and improved prognosis, early identification of co-morbid depression in diabetic patients is warranted. the WHO-5 well-being index (WHO-5) has been used to screen for depression in diabetic patients, and its Chinese version (WHO-5-C) has been validated. However, its psychometric properties remain to be further validated in the type 2 diabetes patient population. The aim of our study was to examine the reliability and validity of the WHO-5-C in patients with type 2 diabetes mellitus. The cross-sectional study was conducted on 200 patients from July 2014 to March 2015. All patients should complete the WHO-5-C, the Patient Health Questionnaire-9 (PHQ-9), the 20-item Problem Areas in Diabetes Scale (PAID-20), the Mini International Neuropsychiatric Interview (M.I.N.I), and Hamilton Rating Scale for Depression (HAM-D). Internal consistency of WHO-5 was revealed by Cronbach's alpha, and constructive validity by confirmatory factor analysis (CFA). Relationship with PHQ-9, HAM-D, and PAID-20 was examined for concurrent validity, and ROC analysis was performed for criterion validity. The WHO-5-C presented satisfactory reliability (Cronbach's alpha = 0.88). CFA confirmed the unidimensional factor structure of WHO-5-C. The WHO-5-C had significant negative correlation with HAM-D (r = -0.610), PHQ-9 (r = -0.694) and PAID-20 (r = -0.466), confirming good concurrent validity. Using M.I.N.I as the gold standard, the cut-off value of WHO-5-C was 42, with a sensitivity of 0.83 and specificity of 0.75. The WHO-5-C holds satisfactory reliability and validity that is suitable for depression screening in type 2 diabetes patients as a short and convenient instrument.
Sections du résumé
BACKGROUND
BACKGROUND
For better disease management and improved prognosis, early identification of co-morbid depression in diabetic patients is warranted. the WHO-5 well-being index (WHO-5) has been used to screen for depression in diabetic patients, and its Chinese version (WHO-5-C) has been validated. However, its psychometric properties remain to be further validated in the type 2 diabetes patient population. The aim of our study was to examine the reliability and validity of the WHO-5-C in patients with type 2 diabetes mellitus.
METHODS
METHODS
The cross-sectional study was conducted on 200 patients from July 2014 to March 2015. All patients should complete the WHO-5-C, the Patient Health Questionnaire-9 (PHQ-9), the 20-item Problem Areas in Diabetes Scale (PAID-20), the Mini International Neuropsychiatric Interview (M.I.N.I), and Hamilton Rating Scale for Depression (HAM-D). Internal consistency of WHO-5 was revealed by Cronbach's alpha, and constructive validity by confirmatory factor analysis (CFA). Relationship with PHQ-9, HAM-D, and PAID-20 was examined for concurrent validity, and ROC analysis was performed for criterion validity.
RESULTS
RESULTS
The WHO-5-C presented satisfactory reliability (Cronbach's alpha = 0.88). CFA confirmed the unidimensional factor structure of WHO-5-C. The WHO-5-C had significant negative correlation with HAM-D (r = -0.610), PHQ-9 (r = -0.694) and PAID-20 (r = -0.466), confirming good concurrent validity. Using M.I.N.I as the gold standard, the cut-off value of WHO-5-C was 42, with a sensitivity of 0.83 and specificity of 0.75.
CONCLUSION
CONCLUSIONS
The WHO-5-C holds satisfactory reliability and validity that is suitable for depression screening in type 2 diabetes patients as a short and convenient instrument.
Identifiants
pubmed: 38031007
doi: 10.1186/s12888-023-05381-9
pii: 10.1186/s12888-023-05381-9
pmc: PMC10685601
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
890Subventions
Organisme : Capital Funds for Health Improvement and Research
ID : CFH2022-2-4012
Organisme : Capital Funds for Health Improvement and Research
ID : CFH2022-2-4012
Organisme : Capital Funds for Health Improvement and Research
ID : CFH2022-2-4012
Organisme : Capital Funds for Health Improvement and Research
ID : CFH2022-2-4012
Organisme : Capital Funds for Health Improvement and Research
ID : CFH2022-2-4012
Organisme : Capital Funds for Health Improvement and Research
ID : CFH2022-2-4012
Informations de copyright
© 2023. The Author(s).
Références
Psychiatry Clin Neurosci. 2009 Apr;63(2):141-6
pubmed: 19335382
Br J Psychiatry. 1988 May;152:660-4
pubmed: 3167442
Health Equity. 2022 Aug 18;6(1):574-594
pubmed: 36081885
J Adv Nurs. 1999 Feb;29(2):316-22
pubmed: 10197930
Acta Diabetol. 2013 Apr;50(2):117-21
pubmed: 20798962
Diabetes Care. 2002 Jan;25(1):35-42
pubmed: 11772898
J Affect Disord. 2004 Feb;78(2):131-40
pubmed: 14706723
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Diabet Med. 2013 Feb;30(2):e63-9
pubmed: 23072401
Diabetes Care. 2000 Jul;23(7):934-42
pubmed: 10895843
Cardiovasc Psychiatry Neurol. 2011;2011:315068
pubmed: 22195273
Psychother Psychosom. 2015;84(3):167-76
pubmed: 25831962
Psychol Bull. 1990 Mar;107(2):238-46
pubmed: 2320703
Eur J Public Health. 2015 Aug;25(4):731-40
pubmed: 25616594
Am J Epidemiol. 2005 Apr 1;161(7):652-60
pubmed: 15781954
Psychosom Med. 2003 May-Jun;65(3):376-83
pubmed: 12764210
BMC Prim Care. 2022 Jun 9;23(1):148
pubmed: 35681150
Gen Hosp Psychiatry. 2011 Sep-Oct;33(5):429-35
pubmed: 21762993
Diabet Med. 2018 Jun;35(6):760-769
pubmed: 29478265
Diabetes Care. 2010 Jan;33(1):38-40
pubmed: 19808922
J Affect Disord. 2017 Jan 15;208:384-391
pubmed: 27810722
Int J Geriatr Psychiatry. 2013 Nov;28(11):1197-204
pubmed: 23463576
Diabetes Care. 2007 Aug;30(8):2003-6
pubmed: 17475940
Endocr Metab Immune Disord Drug Targets. 2018;18(4):371-378
pubmed: 29165096
Front Med (Lausanne). 2022 May 10;9:759499
pubmed: 35620713
Psychosom Med. 2001 Jul-Aug;63(4):619-30
pubmed: 11485116
Diabetes Care. 2004 Sep;27(9):2154-60
pubmed: 15333477
Exp Clin Endocrinol Diabetes. 2010 Jun;118(6):364-7
pubmed: 20140846
Diabetes Res Clin Pract. 2022 Jan;183:109119
pubmed: 34879977
Mov Disord. 2010 Apr 30;25(6):777-83
pubmed: 20108365
Diabetes Metab Syndr Obes. 2021 Nov 02;14:4433-4441
pubmed: 34754208
Diabetes Care. 2007 Sep;30(9):2222-7
pubmed: 17536067
PLoS One. 2020 Apr 16;15(4):e0231924
pubmed: 32298385
Qual Life Res. 2018 May;27(5):1323-1333
pubmed: 29492743
Diabetes Res Clin Pract. 2020 Jan;159:107970
pubmed: 31805355
Diabetes Care. 2005 Nov;28(11):2668-72
pubmed: 16249537
Diabetes Metab Syndr Obes. 2022 Oct 28;15:3303-3317
pubmed: 36329807
Diabetes Metab Syndr Obes. 2018 Jul 10;11:333-343
pubmed: 30022843
Psychoneuroendocrinology. 2018 Mar;89:256
pubmed: 29277432
Diabetes Res Clin Pract. 2017 Oct;132:27-35
pubmed: 28783530
Int J Environ Res Public Health. 2022 Apr 06;19(7):
pubmed: 35410094
Cardiovasc Diabetol. 2018 Jan 24;17(1):19
pubmed: 29368650
Br J Health Psychol. 2008 May;13(Pt 2):311-25
pubmed: 17535497
J Diabetes Complications. 2012 Jan-Feb;26(1):10-6
pubmed: 22226484
Psychiatry Clin Neurosci. 2007 Feb;61(1):112-9
pubmed: 17239048
Health Technol Assess. 2020 Jun;24(28):1-232
pubmed: 32568666
J Affect Disord. 2021 Mar 15;283:30-35
pubmed: 33516084
Front Public Health. 2022 Mar 30;10:872436
pubmed: 35433612